MSU is teaming up with Grand Rapids, Mich.-based Spectrum Health for the five-year research project. The research will focus on adapting approved medications to treat other rare diseases, called orphan diseases. An orphan disease affects less than 200,000 people in the U.S.; the researchers aim to find new treatments for about 6,000 orphan diseases, according to the report.
Through the partnership, the organizations will also use an additional $867,000 grant to fund “innovative uses” of EHRs from the Spectrum Health – MSU Alliance. The research team will use a next generation sequencing approach to match molecular and genomic characteristics of rare diseases against the EHR databases to show which of the existing compounds act on certain characteristics.
“Every drug has a unique fingerprint,” said Bin Chen, PhD, assistant pediatrics and human development professor at MSU, according to the publication. “Then we can match disease fingerprints to individual drug fingerprints.”
The research project will initially focus on three diseases: multiple organ dysfunction syndrome, diffuse intrinsic pontine glioma brain tumor and a type of liver cancer called hepatocellular carcinoma.
More articles on health IT:
Computer glitches caused delays in patient care at Hackensack Meridian Health, nurses say
Banner Health agrees to pay $6M to settle data breach lawsuit
Newly HIPAA-compliant Adstream marketing platform to expand healthcare offerings
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
